×
QQQ   291.71 (+1.01%)
AAPL   145.16 (+1.57%)
MSFT   267.37 (+0.44%)
META   169.41 (-0.21%)
GOOGL   2,323.12 (+1.38%)
AMZN   114.70 (+0.32%)
TSLA   717.39 (+3.19%)
NVDA   155.95 (+3.07%)
NIO   22.93 (+10.08%)
BABA   124.32 (+4.37%)
AMD   78.57 (+4.27%)
MU   58.31 (+1.64%)
CGC   2.69 (+1.51%)
T   21.05 (-0.19%)
GE   62.68 (+1.80%)
F   11.44 (+3.44%)
DIS   96.93 (+0.88%)
AMC   12.79 (+1.75%)
PFE   53.22 (+0.89%)
PYPL   73.72 (+0.66%)
NFLX   186.64 (+1.40%)
QQQ   291.71 (+1.01%)
AAPL   145.16 (+1.57%)
MSFT   267.37 (+0.44%)
META   169.41 (-0.21%)
GOOGL   2,323.12 (+1.38%)
AMZN   114.70 (+0.32%)
TSLA   717.39 (+3.19%)
NVDA   155.95 (+3.07%)
NIO   22.93 (+10.08%)
BABA   124.32 (+4.37%)
AMD   78.57 (+4.27%)
MU   58.31 (+1.64%)
CGC   2.69 (+1.51%)
T   21.05 (-0.19%)
GE   62.68 (+1.80%)
F   11.44 (+3.44%)
DIS   96.93 (+0.88%)
AMC   12.79 (+1.75%)
PFE   53.22 (+0.89%)
PYPL   73.72 (+0.66%)
NFLX   186.64 (+1.40%)
QQQ   291.71 (+1.01%)
AAPL   145.16 (+1.57%)
MSFT   267.37 (+0.44%)
META   169.41 (-0.21%)
GOOGL   2,323.12 (+1.38%)
AMZN   114.70 (+0.32%)
TSLA   717.39 (+3.19%)
NVDA   155.95 (+3.07%)
NIO   22.93 (+10.08%)
BABA   124.32 (+4.37%)
AMD   78.57 (+4.27%)
MU   58.31 (+1.64%)
CGC   2.69 (+1.51%)
T   21.05 (-0.19%)
GE   62.68 (+1.80%)
F   11.44 (+3.44%)
DIS   96.93 (+0.88%)
AMC   12.79 (+1.75%)
PFE   53.22 (+0.89%)
PYPL   73.72 (+0.66%)
NFLX   186.64 (+1.40%)
QQQ   291.71 (+1.01%)
AAPL   145.16 (+1.57%)
MSFT   267.37 (+0.44%)
META   169.41 (-0.21%)
GOOGL   2,323.12 (+1.38%)
AMZN   114.70 (+0.32%)
TSLA   717.39 (+3.19%)
NVDA   155.95 (+3.07%)
NIO   22.93 (+10.08%)
BABA   124.32 (+4.37%)
AMD   78.57 (+4.27%)
MU   58.31 (+1.64%)
CGC   2.69 (+1.51%)
T   21.05 (-0.19%)
GE   62.68 (+1.80%)
F   11.44 (+3.44%)
DIS   96.93 (+0.88%)
AMC   12.79 (+1.75%)
PFE   53.22 (+0.89%)
PYPL   73.72 (+0.66%)
NFLX   186.64 (+1.40%)
NASDAQ:MRUS

Merus Stock Forecast, Price & News

$24.00
+0.44 (+1.87%)
(As of 07/7/2022 09:56 AM ET)
Add
Compare
Today's Range
$23.81
$24.16
50-Day Range
$13.98
$23.56
52-Week Range
$13.47
$33.09
Volume
436 shs
Average Volume
338,941 shs
Market Capitalization
$1.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.43

Merus MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
72.7% Upside
$41.43 Price Target
Short Interest
Bearish
12.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.48) to ($2.62) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.47 out of 5 stars

Medical Sector

1001st out of 1,433 stocks

Pharmaceutical Preparations Industry

494th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

Merus logo

About Merus (NASDAQ:MRUS) Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Analysts Set Merus (NASDAQ:MRUS) Price Target at $40.83
Merus (NASDAQ:MRUS) Shares Gap Up to $18.98
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRUS
Fax
N/A
Employees
117
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/07/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$41.43
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+72.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85714285714286
Research Coverage
7 Analysts

Profitability

Net Income
$-66,820,000.00
Net Margins
-143.77%
Pretax Margin
-143.58%

Debt

Sales & Book Value

Annual Sales
$49.11 million
Book Value
$8.15 per share

Miscellaneous

Free Float
42,287,000
Market Cap
$1.05 billion
Optionable
Not Optionable
Beta
0.91














Merus Frequently Asked Questions

Should I buy or sell Merus stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Merus stock.
View analyst ratings for Merus
or view top-rated stocks.

What is Merus' stock price forecast for 2022?

7 brokers have issued twelve-month price targets for Merus' stock. Their MRUS stock forecasts range from $33.00 to $45.00. On average, they expect Merus' share price to reach $41.43 in the next year. This suggests a possible upside of 72.6% from the stock's current price.
View analysts' price targets for Merus
or view top-rated stocks among Wall Street analysts.

How has Merus' stock price performed in 2022?

Merus' stock was trading at $31.80 at the start of the year. Since then, MRUS shares have decreased by 24.5% and is now trading at $24.00.
View the best growth stocks for 2022 here
.

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Merus
.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) announced its quarterly earnings results on Monday, May, 9th. The biotechnology company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.23. The biotechnology company earned $11.66 million during the quarter, compared to the consensus estimate of $8.55 million. Merus had a negative trailing twelve-month return on equity of 29.02% and a negative net margin of 143.77%.
View Merus' earnings history
.

Who are Merus' key executives?

Merus' management team includes the following people:
  • Dr. Sven Ante Lundberg M.D., CEO, Pres, Principal Financial Officer & Exec. Director (Age 59, Pay $990.53k)
  • Mr. Peter B. Silverman J.D., Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal (Age 44, Pay $677.96k)
  • Mr. Hui Liu Ph.D., Chief Bus. Officer, Exec. VP & Head of Merus U.S. (Age 55, Pay $605.93k)
  • Dr. Hennie Hoogenboom, Co-Founder and Scientific Advisor
  • Harry Shuman, Chief Accounting Officer
  • Mr. Cornelis Adriaan de Kruif Ph.D., CTO & Exec. VP (Age 57)
  • Dr. Cecilia Anna Wilhelmina Geuijen Ph.D., Chief Scientific Officer & Sr. VP
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. Alexander Berthold Hendrik Bakker Ph.D., Chief Devel. Officer & Exec. VP (Age 55)
  • Dr. Andrew Joe M.D., Chief Medical Officer & Sr. VP (Age 55)

What other stocks do shareholders of Merus own?

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $24.00.

How much money does Merus make?

Merus (NASDAQ:MRUS) has a market capitalization of $1.05 billion and generates $49.11 million in revenue each year. The biotechnology company earns $-66,820,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does Merus have?

Merus employs 117 workers across the globe.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The official website for Merus is www.merus.nl. The biotechnology company can be reached via phone at (130) 253-8800 or via email at enquiries@merus.nl.

This page (NASDAQ:MRUS) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.